updated 12/7/2010 9:16:38 AM ET 2010-12-07T14:16:38

LYON, France, Dec. 7, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today that its Sonolith lithotripter products, including Sonolith i-sys and Sonolith i-move, has been exclusively registered by UGAP, the French Public Purchasing Agency. UGAP is the government agency charged with evaluating devices, selecting providers and referencing technologies in all sectors, particularly the healthcare sector.

Experts from UGAP regularly organize tender offers to tightly assess and compare costs and performance of existing technologies. This process facilitates the purchasing cycle of all public organizations, particularly hospitals and clinics. When UGAP exclusively registers a device and recommends its technology as a reference, it validates the superiority of the equipment and its performance. Based on this registration, hospitals and clinics do not need to follow normal tender regulations, hence benefiting from a fast-track process and eliminating competition.

Pierre Reboul, Sales Director of EDAP TMS France, commented, "We are very enthusiastic about UGAP exclusively selecting our lithotripsy range of products. This recommendation facilitates and accelerates purchasing cycles for our French clients, avoiding a lengthy consulting and bid process. UGAP's endorsement is a strong validation of EDAP's business in France, and particularly its leadership in lithotripsy."

Marc Oczachowski, Chief Executive Officer of EDAP TMS, added, "For more than thirty years, EDAP has been offering a broad range of innovative lithotripters, regularly updated to adapt to state of the art technology and urologists needs. This recommendation and the addition of LUMENIS Holmium lasers, already selected by UGAP, will allow EDAP to offer a complete and performing range of urology products in France."


EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, http://www.hifu-planet.com.

          Investor Relations / Legal Affairs
          Blandine Confort
          +33 4 72 15 31 72

          The Ruth Group
          Stephanie Carrington 

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com